Skip to main content
Abbott India Ltd. logo

Abbott India Ltd. — Investor Relations & Filings

Ticker · ABBOTINDIA ISIN · INE358A01014 LEI · 5493008KZ9E3HFRN6T46 BSE.NS Manufacturing
Filings indexed 448 across all filing types
Latest filing 2020-06-08 Regulatory Filings
Country IN India
Listing BSE.NS ABBOTINDIA

About Abbott India Ltd.

https://www.abbott.co.in

Abbott India Ltd. is a pharmaceutical entity focused on providing high-quality healthcare solutions through a diverse portfolio of trusted brands. The company specializes in several key therapeutic areas, including women's health, gastroenterology, cardiology, metabolic disorders, primary care, and the central nervous system. Its product range features well-known formulations such as Duphaston, Thyronorm, Udiliv, Vertin, and Digene. The organization leverages advanced manufacturing capabilities and an extensive distribution network to serve healthcare professionals and patients. It emphasizes science-based innovation and clinical excellence to address evolving medical needs. By maintaining a strong focus on patient outcomes and therapeutic efficacy, the company has established itself as a reliable provider of pharmaceutical products across various specialized and general medical segments.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose a copy of the Audited Financial ....
Regulatory Filings
2020-06-08 English
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors ....
Regulatory Filings
2020-06-08 English
Pursuant to Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform ....
Regulatory Filings
2020-06-08 English
This is further to our letter dated May 5, 2020 enclosing Postal Ballot Notice ("Notice") dated April 27, 2020 issued to the Members of the Company for seeking their approval, by way of ....
Regulatory Filings
2020-06-07 English
Please find enclosed the copies of Public Notice published as per Regulation 47 (3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Regulatory Filings
2020-05-29 English
ABBOTT INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2020 ,inter alia, to consider and approve the text of Audited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter from Abbott India Limited addressed to the stock exchange (BSE Limited) dated May 29, 2020. It informs about a scheduled Board of Directors meeting on June 8, 2020, to consider and approve the audited financial results and audited financial statements for the quarter and year ended March 31, 2020, and to recommend a dividend. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document is an announcement of an upcoming board meeting and the intention to approve financial results, not the financial report itself. The document length is 2667 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement under SEBI regulations about the board meeting and financial results approval, not the actual financial report or earnings release.
2020-05-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.